

Copyright (c) 1993 - 2003 CompuTech Inc
Software version 5.1.3

pred.	No.	Score	Query	Match	Length	DB	ID	Description
gencore version 5.1.3	1	55	100.0	11	22	AAB82019		Human hepreceptor
Copyright (c) 1993 - 2003 Compugen Ltd.	2	55	100.0	12	22	AAB82018		Human hepreceptor
protein search, using sw model	3	55	100.0	13	22	AAB82017		Human hepreceptor
on Aug: Jan'97 16, 2003, 15:34:37 (without alignments)	4	55	100.0	14	22	AAB82016		Human hepreceptor
scoring table: BLOSUM62	5	55	100.0	15	22	AAM3356		Amino acid sequence
GapP 10.0 ; GapWt 0.5	6	55	100.0	16	22	ABG29165		Human peptide eno
title: US-09-856-070-24	7	55	100.0	17	22	ABB39680		Human brain express
perfect score: 55	8	55	100.0	18	22	AAM3356		Human bone marrow
sequence: 1 ELMRLQDYEE 11	9	55	100.0	19	22	AAM73042		Human peptide eno
total number of hits satisfying clustering parameters:	10	55	100.0	20	22	AAB39681		Novel human diaqno
minimum DB seq length: 0	11	55	100.0	21	22	ABG4876		Novel human diaqno
maximum DB seq length: 20000000	12	55	100.0	22	22	ABG19448		Novel human diaqno
post-processing: Minimum Match 0.9	13	55	100.0	23	22	AAG3196		Novel human diaqno
Maximum Match 1.0%	14	55	100.0	24	22	AAG3196		Novel human diaqno
listing first 45 summaries	15	55	100.0	25	22	AAG3196		Novel human diaqno
database :	16	55	100.0	26	22	AHC19445		Novel human diaqno
A_Geneseq_1010102.*	17	55	100.0	27	22	ABG29077		Novel human diaqno
1: /SIDS2/seqdata/geneseq/geneseq-emb1/AA190 DAT:*	18	55	100.0	28	22	AAC8197		Novel human diaqno
2: /SIDS2/seqdata/geneseq/geneseq-emb1/AA190 DAT:*	19	55	100.0	29	22	AAG3197		Novel human diaqno
3: /SIDS2/seqdata/geneseq/geneseq-emb1/AA190 DAT:*	20	55	100.0	30	22	AAG3197		Novel human diaqno
4: /SIDS2/seqdata/geneseq/geneseq-emb1/AA190 DAT:*	21	55	100.0	31	22	AAG3197		Novel human diaqno
5: /SIDS2/seqdata/geneseq/geneseq-emb1/AA190 DAT:*	22	55	100.0	32	22	AAG3197		Novel human diaqno
6: /SIDS2/seqdata/geneseq/geneseq-emb1/AA190 DAT:*	23	55	100.0	33	22	AAG3197		Novel human diaqno
7: /SIDS2/seqdata/geneseq/geneseq-emb1/AA190 DAT:*	24	55	100.0	34	22	AAG3197		Novel human diaqno
8: /SIDS2/seqdata/geneseq/geneseq-emb1/AA190 DAT:*	25	55	100.0	35	22	AAG3197		Novel human diaqno
9: /SIDS2/seqdata/geneseq/geneseq-emb1/AA190 DAT:*	26	55	100.0	36	22	AAG3197		Novel human diaqno
10: /SIDS2/seqdata/geneseq/geneseq-emb1/AA190 DAT:*	27	55	100.0	37	22	AAG3197		Novel human diaqno
11: /SIDS2/seqdata/geneseq/geneseq-emb1/AA190 DAT:*	28	55	100.0	38	22	AAG3197		Novel human diaqno
12: /SIDS2/seqdata/geneseq/geneseq-emb1/AA190 DAT:*	29	55	100.0	39	22	AAG3197		Novel human diaqno
13: /SIDS2/seqdata/geneseq/geneseq-emb1/AA190 DAT:*	30	55	100.0	40	22	AAG3197		Novel human diaqno
14: /SIDS2/seqdata/geneseq/geneseq-emb1/AA190 DAT:*	31	55	100.0	41	22	AAG3197		Novel human diaqno
15: /SIDS2/seqdata/geneseq/geneseq-emb1/AA190 DAT:*	32	55	100.0	42	22	AAG3197		Novel human diaqno
16: /SIDS2/seqdata/geneseq/geneseq-emb1/AA190 DAT:*	33	55	100.0	43	22	AAG3197		Novel human diaqno
17: /SIDS2/seqdata/geneseq/geneseq-emb1/AA190 DAT:*	34	55	100.0	44	22	AAG3197		Novel human diaqno
18: /SIDS2/seqdata/geneseq/geneseq-emb1/AA190 DAT:*	35	55	100.0	45	22	AAG3197		Novel human diaqno
19: /SIDS2/seqdata/geneseq/geneseq-emb1/AA190 DAT:*	36	55	100.0	46	22	AAG3197		Novel human diaqno
20: /SIDS2/seqdata/geneseq/geneseq-emb1/AA190 DAT:*	37	55	100.0	47	22	AAG3197		Novel human diaqno
21: /SIDS2/seqdata/geneseq/geneseq-emb1/AA190 DAT:*	38	55	100.0	48	22	AAG3197		Novel human diaqno
22: /SIDS2/seqdata/geneseq/geneseq-emb1/AA190 DAT:*	39	55	100.0	49	22	AAG3197		Novel human diaqno
23: /SIDS2/seqdata/geneseq/geneseq-emb1/AA190 DAT:*	40	55	100.0	50	22	AAG3197		Novel human diaqno
pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.	41	74.5	26	22	AAY2744		Homo sapiens	
	42	74.5	26	22	GB2354241-A		OS	
	43	74.5	26	22	GB2354241-B		XX	
	44	74.5	26	22	GB2354241-C		XX	
	45	74.5	26	22	GB2354241-D		XX	
	46	74.5	26	22	GB2354241-E		XX	
	47	74.5	26	22	GB2354241-F		XX	
	48	74.5	26	22	GB2354241-G		XX	
	49	74.5	26	22	GB2354241-H		XX	
	50	74.5	26	22	GB2354241-I		XX	
	51	74.5	26	22	GB2354241-J		XX	
	52	74.5	26	22	GB2354241-K		XX	
	53	74.5	26	22	GB2354241-L		XX	
	54	74.5	26	22	GB2354241-M		XX	
	55	74.5	26	22	GB2354241-N		XX	
	56	74.5	26	22	GB2354241-O		XX	
	57	74.5	26	22	GB2354241-P		XX	
	58	74.5	26	22	GB2354241-Q		XX	
	59	74.5	26	22	GB2354241-R		XX	
	60	74.5	26	22	GB2354241-S		XX	
	61	74.5	26	22	GB2354241-T		XX	
	62	74.5	26	22	GB2354241-U		XX	
	63	74.5	26	22	GB2354241-V		XX	
	64	74.5	26	22	GB2354241-W		XX	
	65	74.5	26	22	GB2354241-X		XX	
	66	74.5	26	22	GB2354241-Y		XX	
	67	74.5	26	22	GB2354241-Z		XX	
	68	74.5	26	22	GB2354241-A		XX	
	69	74.5	26	22	GB2354241-B		XX	
	70	74.5	26	22	GB2354241-C		XX	
	71	74.5	26	22	GB2354241-D		XX	
	72	74.5	26	22	GB2354241-E		XX	
	73	74.5	26	22	GB2354241-F		XX	
	74	74.5	26	22	GB2354241-G		XX	
	75	74.5	26	22	GB2354241-H		XX	
	76	74.5	26	22	GB2354241-I		XX	
	77	74.5	26	22	GB2354241-J		XX	
	78	74.5	26	22	GB2354241-K		XX	
	79	74.5	26	22	GB2354241-L		XX	
	80	74.5	26	22	GB2354241-M		XX	
	81	74.5	26	22	GB2354241-N		XX	
	82	74.5	26	22	GB2354241-O		XX	
	83	74.5	26	22	GB2354241-P		XX	
	84	74.5	26	22	GB2354241-Q		XX	
	85	74.5	26	22	GB2354241-R		XX	
	86	74.5	26	22	GB2354241-S		XX	
	87	74.5	26	22	GB2354241-T		XX	
	88	74.5	26	22	GB2354241-U		XX	
	89	74.5	26	22	GB2354241-V		XX	
	90	74.5	26	22	GB2354241-W		XX	
	91	74.5	26	22	GB2354241-X		XX	
	92	74.5	26	22	GB2354241-Y		XX	
	93	74.5	26	22	GB2354241-Z		XX	
	94	74.5	26	22	GB2354241-A		XX	
	95	74.5	26	22	GB2354241-B		XX	
	96	74.5	26	22	GB2354241-C		XX	
	97	74.5	26	22	GB2354241-D		XX	
	98	74.5	26	22	GB2354241-E		XX	
	99	74.5	26	22	GB2354241-F		XX	
	100	74.5	26	22	GB2354241-G		XX	
	101	74.5	26	22	GB2354241-H		XX	
	102	74.5	26	22	GB2354241-I		XX	
	103	74.5	26	22	GB2354241-J		XX	
	104	74.5	26	22	GB2354241-K		XX	
	105	74.5	26	22	GB2354241-L		XX	
	106	74.5	26	22	GB2354241-M		XX	
	107	74.5	26	22	GB2354241-N		XX	
	108	74.5	26	22	GB2354241-O		XX	
	109	74.5	26	22	GB2354241-P		XX	
	110	74.5	26	22	GB2354241-Q		XX	
	111	74.5	26	22	GB2354241-R		XX	
	112	74.5	26	22	GB2354241-S		XX	
	113	74.5	26	22	GB2354241-T		XX	
	114	74.5	26	22	GB2354241-U		XX	
	115	74.5	26	22	GB2354241-V		XX	
	116	74.5	26	22	GB2354241-W		XX	
	117	74.5	26	22	GB2354241-X		XX	
	118	74.5	26	22	GB2354241-Y		XX	
	119	74.5	26	22	GB2354241-Z		XX	
	120	74.5	26	22	GB2354241-A		XX	
	121	74.5	26	22	GB2354241-B		XX	
	122	74.5	26	22	GB2354241-C		XX	
	123	74.5	26	22	GB2354241-D		XX	
	124	74.5	26	22	GB2354241-E		XX	
	125	74.5	26	22	GB2354241-F		XX	
	126	74.5	26	22	GB2354241-G		XX	
	127	74.5	26	22	GB2354241-H		XX	
	128	74.5	26	22	GB2354241-I		XX	
	129	74.5	26	22	GB2354241-J		XX	
	130	74.5	26	22	GB2354241-K		XX	
	131	74.5	26	22	GB2354241-L		XX	
	132	74.5	26	22	GB2354241-M		XX	
	133	74.5	26	22	GB2354241-N		XX	
	134	74.5	26	22	GB2354241-O		XX	
	135	74.5	26	22	GB2354241-P		XX	
	136	74.5	26	22	GB2354241-Q		XX	
	137	74.5	26	22	GB2354241-R		XX	
	138	74.5	26	22	GB2354241-S		XX	
	139	74.5	26	22	GB2354241-T		XX	
	140	74.5	26	22	GB2354241-U		XX	
	141	74.5	26	22	GB2354241-V		XX	
	142	74.5	26	22	GB2354241-W		XX	
	143	74.5	26	22	GB2354241-X		XX	
	144	74.5	26	22	GB2354241-Y		XX	
	145	74.5	26	22	GB2354241-Z		XX	
	146	74.5	26	22	GB2354241-A		XX	
	147	74.5	26	22	GB2354241-B		XX	
	148	74.5	26	22	GB2354241-C		XX	
	149	74.5	26	22	GB2354241-D		XX	
	150	74.5	26	22	GB2354241-E		XX	
	151	74.5	26	22	GB2354241-F		XX	
	152	74.5	26	22	GB2354241-G		XX	
	153	74.5	26	22	GB2354241-H		XX	
	154	74.5	26	22	GB2354241-I		XX	
	155	74.5	26	22	GB2354241-J		XX	
	156	74.5	26	22	GB2354241-K		XX	
	157	74.5	26	22	GB2354241-L		XX	
	158	74.5	26	22	GB2354241-M		XX	
	159	74.5	26	22	GB2354241-N		XX	
	160	74.5	26	22	GB2354241-O		XX	
	161	74.5	26	22	GB2354241-P		XX	
	162	74.5	26	22	GB2354241-Q		XX	
	163	74.5	26	22	GB2354241-R		XX	
	164	74.5	26	22	GB2354241-S		XX	
	165	74.5	26	22	GB2354241-T		XX	
	166	74.5	26	22	GB2354241-U		XX	
	167	74.5	26	22	GB2354241-V		XX	
	168	74.5	26	22	GB2354241-W		XX	
	169	74.5	26	22	GB2354241-X		XX	
	170	74.5	26	22	GB2354241-Y		XX	
	171	74.5	26	22	GB2354241-Z		XX	
	172	74.5	26	22	GB2354241-A		XX	
	173	74.5	26	22	GB2354241-B		XX	
	174	74.5	26	22	GB2354241-C		XX	

XX	Novel regulatory or unfolding peptides of ezrin that binds to PT hepreceptor, useful for inducing immune response for treating PT infectious diseases and cancer -	CC HIV related dementia; the present peptide binds to domain A of the PT hepreceptor (AAB82019).
PS	Claim 26: Page 37: 42pp; English.	CC
XX	The hepreceptor is a novel active site in human ezrin. Ezrin regulates the structure of the cortical cytoskeleton to control cell surface topography. The present invention relates to peptides (see AAB82021 to AAB82041) that bind to hepreceptor with greater affinity than HEP1 (see AAB82046). The hepreceptor binding peptides are useful for inducing immune response, and for treating infectious diseases, cancer and HIV related dementia. The present peptide binds to domain A of the hepreceptor (AAB82019).	CC
XX	Sequence 11 AA;	CC
SQ	Query Match 100.0%; Score 55; 108 22; Length: 11; Best Local Similarity 100.0%; Pred. No. 0.0047; Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	CC
XX	Query Match 100.0%; Score 55; 108 22; Length: 12; Best Local Similarity 100.0%; Pred. No. 0.0047; Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	CC
QY	1 ELMERLOYEE 11 11111111	CC
DB	2 ELMERLOYEE 12	CC
		RESULT 3
		AAB82037
ID	AAB82037 standard; peptide: 13 AA.	
XX		
AC	AAB82037;	
XX		
DT	13-JUN-2001 (first entry)	
DE	Human hepreceptor domain A binding peptide Rupe2032.	
XX		
KW	Human; hepreceptor; cytostatic; anti-HIV; antibiotic; nootropic; immune response inducer; ezrin; infectious diseases; cancer; HIV related dementia.	
XX		
OS	Homo sapiens.	
XX		
FH	Location/Qualifiers	
FT	Modified-site 11 /note- "optionally phosphorylated"	
XX		
PN	GB254241-A.	
XX		
PD	21-MAR-2001.	
XX		
PF	17-SEP-1999; 99GB-0021881.	
XX		
PR	17-SEP-1999; 99GB-0021881.	
XX		
PA	(HOLM/) HOLMS R D.	
XX		
PT	Holms RD;	
XX		
DR	WPI: 2001-252287/31.	
XX		
PR	Novel regulatory or unfolding peptides of ezrin that binds to PT hepreceptor, useful for inducing immune response for treating PT infectious diseases and cancer -	
XX		
CC	The hepreceptor is a novel active site in human ezrin. Ezrin regulates the structure of the cortical cytoskeleton to control cell surface topography. The present invention relates to peptides (see AAB82021 to AAB82041) that bind to hepreceptor with greater affinity than HEP1 (see AAB82046). The hepreceptor binding peptides are useful for inducing immune response, and for treating infectious diseases, cancer and HIV related dementia. The present peptide binds to domain A of the hepreceptor (AAB82019).	
XX		
SQ	Sequence 13 AA;	
PS	Query Match 100.0%; Score 55; 108 22; Length: 13;	
XX	Best Local Similarity 100.0%; Pred. No. 0.0051;	
XX	Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	1 ELMERLOYEE 11 11111111	
DB	3 ELMERLOYEE 13	

RESULT 4
 AAB82020
 ID AAB82020 standard; peptide: 34 AA.
 XX
 AC AAB82020;
 XX
 DT 13-JUN-2001 (first entry)
 XX Human hepreceptor domain B.
 DE Human hepreceptor domain B.
 XX
 KW hepreceptor domain B; cytostatic; anti-HIV; antibiotic;
 KW oncotropic; immune response inducer; ezrin; infectious diseases; cancer;
 KW HIV-related dementia.
 XX Homo sapiens.
 OS Ruben SM, Barash SC, Birse CE, Rosen CA;
 XX
 FH Key location/Qualifiers:
 FI Modified-site 14 /note= "optionally phosphorylated"
 FT
 XX Nucleic acids encoding 4277 human colon cancer-associated polypeptides,
 PN GR234241-A.
 XX
 PD 21-MAR-2001.
 XX
 PF 17-SEP-1999; 99GB-0021881.
 XX
 PR 17-SEP-1999; 99GB-0021881.
 PA (HOLM/ HOLMS R D.
 PI Holms RD;
 DR 2001 29328731
 XX Novel regulatory or unfolded peptides of ezrin that binds to,
 PT hepreceptor, useful for inducing immune response for treating
 CC infectious diseases and cancer.
 XX
 PS Claim 5; Page 36; 42pp; English.
 XX The present sequence is domain B of human hepreceptor of human ezrin. The
 CC hepreceptor is a novel active site in human ezrin. Ezrin regulates the
 structure of the cortical cytoskeleton to control cell surface.
 CC Topography. The present invention relates to peptides (see AAB82021 to
 CC AAB82041) that bind to hepreceptor with greater affinity than IEP1 (see
 CC AAB82046). The hepreceptor binding peptides are useful for inducing
 CC immune response, and for treating infectious diseases, cancer and
 CC HIV-related dementia. The present sequence assembles into two
 CC anti-parallel helices with hepreceptor domain A (see AAB8201).
 XX Sequence 34 AA:
 SQ 1 ELMRLQDYE 11
 Query Match 100.0%; Score 55; DB 22; Length 34.
 Best local Similarity 100.0%; pred No. 0.014;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 YY 1 ELMRLQDYE 11
 DB 6 ELMRLQDYE 16
 RESULT 5
 AAG73954
 ID AAG73954 standard; Protein: 436 AA.
 XX
 AC AAC73954;
 XX
 DT 03-SEP-2001 (1st entry)
 XX Human colon cancer antigen protein SEQ ID No:4718.
 DE Human colon cancer antigen protein SEQ ID No:4718.
 KW

KW colorectal carcinoma.
 XX Homo sapiens.
 OS
 XX
 PN WO200122923-A2.
 XX
 PI 05-APR-2001.
 XX
 PF 28-SEP-2002; 2000WC-MS26524.
 XX
 PR 29-SEP-1999; 99US-0157137.
 PR 03-NOV-1999; 99US-0163280.
 XX
 PA (HUMA) HUMAN GENOME SCI INC.
 XX
 PI Ruben SM, Barash SC, Birse CE, Rosen CA;
 XX
 WF-1; 29G; 235357-24.
 DR NPSDB; AAH33385.
 XX
 PT Nucleic acids encoding 4277 human colon cancer-associated polypeptides,
 PT useful for preventing, diagnosing and/or treating colorectal cancers -
 XX
 PS Claim 11; Page 6520-6521; 9803pp; English.
 XX
 AAH32943 to AAH37195 and AAH373514 to AAH77788 represent human colon
 CC cancer-associated nucleic acid molecules (N) and proteins (P), where
 CC the proteins are collectively known as "colon cancer antigens". The colon
 CC cancer antigens have cytostatic activity and can be used in gene
 CC therapy and vaccine production. N and P may be used in the prevention,
 CC diagnosis and treatment of diseases associated with inappropriate P
 CC expression. For example, N and P may be used to treat disorders
 CC associated with decreased expression by rectifying mutations or deletions
 CC in a patient's genome that affect the activity of P by expressing
 CC inactive proteins or to supplement the patient's own production of P.
 CC Additionally, it may be used to produce the colon cancer associated P,
 CC by inserting the nucleic acids into a host cell and culturing the cell
 CC to express the proteins. N and P can be used in the prevention, diagnosis
 CC and treatment of colorectal carcinomas and cancers. AAH37196 to AAH37204
 CC and AAH77786 represent sequences used in the exemplification of the
 CC present invention.
 CC N.B.: Links to 682 and 743 of the sequence listing were
 CC missing at time of publication, meaning no sequences are present for
 CC seq in No. 6127 to 1052, 7921 and 7922.
 XX
 SQ Sequence 436 AA:
 YY 1 ELMRLQDYE 11
 Query Match 100.0%; Score 55; DB 22; Length 34.
 Best local Similarity 100.0%; pred No. 0.018;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 YY 1 ELMRLQDYE 11
 DB 196 ELMRLQDYE 206
 RESULT 6
 AAY27443
 ID AAY27443 standard; protein: 586 AA.
 XX
 AC AAY27443;
 XX
 DT 26-NOV-1999 (first entry)
 XX
 DE Amino acid sequence of human ezrin polypeptide.
 XX
 KW Pharmaceutical; ezrin; mutant; tumor; metastasis; human.
 XX
 OS Homo sapiens.
 XX
 FU Key
 FT Misc-difference 354 Location/Qualifiers
 FT /note= "the tyr at this position can be mutated"

XX AAC97991 to AAC98763 encode the human colon cancer associated proteins, XX called human colon cancer antigens, given in AAB51234 to AAB4906. The XX human colon cancer antigens can have cytoskeletal, cardiac, muscular, XX neuroprotective, immunomodulatory, gynaecological, autoinflammatory, XX pulmonary, nephrotoxic, anti-infective and antibacterial activities, and XX can be used in gene therapy. The colon cancer antigen polypeptides, and XX proteins and antibodies to the proteins are useful for the prevention, XX treatment and diagnosis of colon disorders, such as colon cancer. The XX chromatopeptides may be used in diagnostics and research, such as for XX chromosome identification, and as hybridisation probes. The proteins XX may also be used to prevent diseases such as neural disorders, immune XX system disorders, muscular disorders, reproductive, disorders, XX gastrointestinal disorders, wounds, tumor disorders, infections XX diseases, and cardiovascular disorders. AAW48764 to AAW48772 and XX AAB54007 represent sequences used in the exemplification of the present XX invention.

XX Sequence 635 AA;

Query Match 100.0%; Score 55; DB 21; Length 635;

Best Local Similarity 100.0%; Pred No. 0.27;

Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ELMRLQDYE 11

Db 395 ELMRLQDYE 405

REFSEQ 9

AAU33060

ID AAU33060 standard; Protein; 52 AA.

XX Novel human secreted protein #3551.

XX Human; vaccination; gene therapy; nutritional supplement;

XX stem cell proliferation; haemopoiesis; nerve tissue regeneration;

XX immune suppression; immune stimulation; anti-inflammatory; leukaemia.

OS Homo sapiens

XX WO20017449-A2.

XX PN 25-OCT-2001.

XX PI 16-APR-2001; 2001WO-US08656.

XX PR 18-APP-2000; 2000W0-0552929

XX PR 26-JAN-2001; 2001US-0770160.

XX PA (HYSE-) HYSEG INC.

XX PI Tang YT, Liu C, Drmanac RT;

XX DR WPI; 2001-611725/70.

XX Nucleic acids encoding a range of human polypeptides, useful in genetic

PT vaccination, testing and therapy.

XX claim 20, Page 762, 765pp, English.

XX The invention relates to novel human secreted polypeptides, the

CC polypeptides and antibodies to the polypeptides are useful for

CC determining the presence of or predisposition to a disease associated

CC with altered levels of polypeptide. The polypeptides are also useful for

CC identifying agents (agonists and antagonists) that bind to them. Cells

CC expressing the proteins are useful for identifying a therapeutic agent

CC for use in treatment of a pathology related to aberrant expression or

CC physiological interactions of the polypeptide. Vectors comprising

CC the nucleic acids encoding the polypeptides and cells genetically
CC engineered to express them are also useful for producing the proteins.
CC The proteins are useful in genetic vaccination, testing and
CC therapy, and can be used as nutritional supplements. They may be used to
CC increase stem cell proliferation, to regulate haematopoiesis; and in
CC bone, cartilage, tendon, skin or nerve tissue growth, or reparation;
CC immune suppression and/or stimulation, as anti-inflammatory agents, and
CC in treatment of leukemias. AAU29510 AAU3306 represent the amino acid
CC sequences of novel human secreted proteins of the invention.
XX SQ sequence 52 AA;

Query Match 85.5%; Score 47; DB 23; Entry 52;

Host Local Similarity 90.4%; Pred No. 0.49;

Matches 167; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1 ELMRLQDYE 11

Db 14 ELMRLQDYE 24

... RESULT 10

AAV27444

ID AAV27444 standard; peptide; 27 AA.

XX AC AAV27444;

XX DT 26-NOV-1999 (First entry)

XX XX Synthetic.

XX FH Key Location/Qualifiers

XX FT Modified-site 1

XX KW Pharmaceutical; eritin; mutant; tumor; antitumour; tetramerization;

XX KW metastasis; human.

XX OS Synthetic.

XX FH Key Location/Qualifiers

XX FT Modified-site 1

XX KW /note= "biotinylated"

XX FT Modified-site 22

XX PT /note= "synthetically phosphorylated"

XX PN WO9947150-A2.

XX XX PD 23-SEP-1999.

XX XX PF 18-MAR-1999; 99W0-EP02054.

XX XX PR 18-MAR-1998; 98US-0040725.

XX XX PA ((CURI-)) INST CURIE.

XX PA ((CURI-)) INSTITUT RECH SCI.

XX PR Arpin M, Crepaldi T, Gautreau A, Louvard D;

XX DR WPI; 1999-561851/47.

XX XX PT New composition for prevention and treatment of tumors and metastasis

PT PT Example 5; Page 14; 31pp; English.

XX PS The invention provides a pharmaceutical composition containing eritin

CC protein, RNA or DNA mutated at lysine 353 or a functional fragment

CC or derivative of the eritin murat. The new composition is useful for

CC prevention and/or treatment of tumors and especially metastasis. The

CC first step involves preparation of an antitumor interaction sequence in

CC tandem with eritin fragment (residues 348-358). This is used in

CC experiments of p85 interaction with phosphorylated eritin peptides.

XX SQ Sequence 27 AA;

Query Match 74.5%; Score 41; DB 20; Length 27;

Best Local Similarity	100.0%	Pred. No.	2-7:	0;	Mismatches	0;	Indels	0;	Gaps	0;	QY	1 ELMURQDYE 10
Matches	8;	Conservative									DB	11111111 279 ELMURQDYE 288
OY	4	ELMURQDYE	1								XX	
DB	17	ELMURQDYE	24								AC	ABG29165 standard; protein: 344 AA.
RESULT 11												
AKI29165		ABG29165	standard; protein: 344 AA.								XX	ABH39680 standard; peptide: 57 AA.
XX		ABG29165;									XX	ABH39680;
AC											XX	
XX											DT	04-FEB-2002 (first entry)
DI	13-FEB-2002	(first entry)									XX	
DE	Novel human diagnostic protein #249156.										DE	Peptide #7186 encoded by human foetal liver single exon probe.
XX											XX	
XX	Human; chromosome mapping; gene mapping; gene therapy; forensic; food supplement; medical imaging; diagnostic; genetic disorder.										KW	Human; foetal liver; gene expression; single exon nucleic acid probe.
XX											OS	Homo sapiens.
OS											OS	
Homosapiens.											PN	WO200157277-A2.
XX											XX	
FN	WO20017507-A2.										PD	09-AUG-2001.
XX											XX	
FD	11-OCT-2001.										PF	30-JAN-2001; 2001WO-US00666.
XX											XX	
UF	30-MAR-2001; 2001WO-US09631.										PR	04-FEB-2000; 2000US-0190312.
XX											PR	26-MAY-2000; 2000US-0207456.
PR	31-MAR-2000; 2000US-0640217.										PR	30-JUN-2000; 2000US-0618408.
PP	24-Aug-2000; 2000US-0640167.										PR	03-AUG-2000; 2000US-0622366.
XX											FR	21-SEP-2003; 2000US-0324687.
PA	(HYSEQ) HYSEQ INC.										PP	27-SEP-2003; 2000US-0216359.
XX											PR	04-OCT-2000; 2000US-0024263.
PA	(MOLE-) MOLECULAR DYNAMICS INC.										XX	
XX											PA	
PT	Patent SG, Barzel DK, Chen W, Rank DR;										XX	
BR	WIPO: 2001-483447/52.										PT	
XX											PT	
PT	Human genome-derived single exon nucleic acid probes useful for analyzing gene expression in human fetal liver -										XX	
XX											XX	
PS	Claim 27; SEQ ID NO 32315; 639pp + sequence listing; English.										PS	Claim 27; SEQ ID NO 32315; 639pp + sequence listing; English.
XX											XX	
CC	The invention relates to a single exon nucleic acid probe for measuring human gene expression in a sample derived from human foetal liver. The single exon nucleic acid probes may be used for predicting, measuring and displaying gene expression in samples derived from human fetal liver. The present sequences is a peptide encoded by a single exon nucleic acid probe of the invention.										CC	The invention relates to a single exon nucleic acid probe for measuring human gene expression in a sample derived from human foetal liver. The single exon nucleic acid probes may be used for predicting, measuring and displaying gene expression in samples derived from human fetal liver. The present sequences is a peptide encoded by a single exon nucleic acid probe of the invention.
CC	Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp://wipo.int/pub/published_pct_sequences .										CC	Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp://wipo.int/pub/published_pct_sequences .
XX											XX	
PS	Claim 20; SEQ ID NO 59524; 103pp; English.										SQ	Sequence 57 AA;
XX											XX	
CC	The invention relates to isolated polynucleotide (I) and poly peptide (II) sequences, (I) is useful as hybridisation probes, polymerase chain reaction (PCR) primers, oligonucleotides, and for characterisation and gene mapping, and in recombinant production of (III). The polynucleotides are also used in diagnostics as expressed sequence tags for identifying expressed genes. (I) is useful in gene therapy techniques to restore normal activity of (II) or to treat disease states involving (II). (II) is useful for generating antibodies against it, detecting or quantitating a polypeptide in tissue, as molecular weight markers and as a food supplement. (II) and its binding partners are useful in medical diagnosis of sites expressing (II). (I) and (II) are useful for treating disorders involving aberrant protein expression or biological activity. The polynucleotide and polypeptide sequences have applications in diagnostics, forensics, gene mapping, identification of mutations responsible for genetic disorders or other traits to assess biodiversity and to produce other types of data and products dependent on DNA and amino acid sequences. ABG0010-ABG30377 represent novel human diagnostic antibody sequences of the invention.										CC	The invention relates to isolated polynucleotide (I) and poly peptide (II) sequences, (I) is useful as hybridisation probes, polymerase chain reaction (PCR) primers, oligonucleotides, and for characterisation and gene mapping, and in recombinant production of (III). The polynucleotides are also used in diagnostics as expressed sequence tags for identifying expressed genes. (I) is useful in gene therapy techniques to restore normal activity of (II) or to treat disease states involving (II). (II) is useful for generating antibodies against it, detecting or quantitating a polypeptide in tissue, as molecular weight markers and as a food supplement. (II) and its binding partners are useful in medical diagnosis of sites expressing (II). (I) and (II) are useful for treating disorders involving aberrant protein expression or biological activity. The polynucleotide and polypeptide sequences have applications in diagnostics, forensics, gene mapping, identification of mutations responsible for genetic disorders or other traits to assess biodiversity and to produce other types of data and products dependent on DNA and amino acid sequences. ABG0010-ABG30377 represent novel human diagnostic antibody sequences of the invention.
CC	Note: The sequence data for this patent did not appear in the printed specification, but was obtained in electronic format directly from WIPO at ftp://wipo.int/pub/published_pct_sequences .										CC	Note: The sequence data for this patent did not appear in the printed specification, but was obtained in electronic format directly from WIPO at ftp://wipo.int/pub/published_pct_sequences .
XX											XX	
SO	Sequence 344 AA;										XX	
Query Match	72.7%	Score 40;	DH 22;	Length 344;							XX	
Best Local Similarity	80.0%	Pred. No.	53;								AC	ABG00396;
Matches	8;	Conservative	1;	Mismatches	1;	Indels	0;	Gaps	0;		XX	
DB	18 ELMLURQDYE 28										DT	05-NOV-2001 (first entry)
RESULT 12												
ABB39680											XX	
XX											AC	ABG0396 standard; protein: 57 AA.
XX											XX	
XX											DT	05-NOV-2001 (first entry)

XX Human brain expressed single exon probe encoded protein SEQ ID No.: 32511.
DE PT
XX PR 34-Feb-2001; 2000US0207052.
PR 26-MAY-2001; 2000US0207056.
IP 30-JUN-2001; 2000US0608408.
IP 04-AUG-2001; 2000US0632499.
IP 21-SEP-2001; 2000US023487.
PR 27-SEP-2001; 2000US023659.
PR 04-OCT-2001; 2000US024263.
XX PA
PN (MOLE-) MOLECULAR DYNAMICS INC.
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
PD XX
PF XX
PP XX
PR XX
PR 04-FEB-2000; 2000US0180312.
PR 26-MAY-2000; 2000US0207456.
PR 30-JUN-2000; 2000US0608408.
PR 04-AUG-2000; 2000US023466.
PR 21-SEP-2000; 2000US0234687.
PR 27-SEP-2000; 2000US0236359.
PR 04-OCT-2001; 2000US024263.
XX PA (MOLE-) MOLECULAR DYNAMICS INC.
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
PR XX
WPI; 2001488900/53.
XX
XX Human brain derived single exon nucleic acid probes useful for
analyzing gene expression in human bone marrow.
XX
Example 4: SEQ ID No.: 33338, 650pp + Sequence Listing; English.
FS
XX The present invention provides a number of single exon nucleic acid
probes which are derived from genomic sequences expressed in the human
bone marrow. They can be used to measure gene expression in bone marrow
samples, which may enable the improved diagnosis and treatment of cancers
such as lymphoma, leukaemia and myeloma. The present sequence is a
protein encoded by one of the probes of the invention.
XX
SQ Sequence 57 AA:
Query Match Score 39; DB 22; Length 57;
Best Local Similarity 70.9%; Pred. No. 13;
Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
AC AAM33256 standard; protein; 57 AA.
XX
QY 1 ELMRLQYE 11
DB 18 ELMRLQYE 28
XX
RESULT 15
AAM33256 standard; protein; 57 AA.
ID AAM33256;
AC AAM33256;
XX
AC AAM33256;
XX LI 17-DEC-2001 (first entry)
XX PR peptide #725; diagnostic probe for 2000US02348714; expression.
XX
QY 1 ELMRLQYE 11
DB 18 ELMRLQYE 28
XX
RESULT 14
AAM73032 standard; protein; 57 AA.
ID AAM73032
AC AAM73032;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human bone marrow expressed probe encoded protein SEQ ID No.: 44448
XX PR peptide #725; diagnostic probe for 2000US02348714; expression.
XX
QY 1 ELMRLQYE 11
DB 18 ELMRLQYE 28
XX
RESULT 14
AAM73032 standard; protein; 57 AA.
ID AAM73032
AC AAM73032;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human bone marrow expressed probe encoded protein SEQ ID No.: 44448
XX PR peptide #725; diagnostic probe for 2000US02348714; expression.
XX
QY 1 ELMRLQYE 11
DB 18 ELMRLQYE 28
XX
OS Homo sapiens
XX PA (MOLE-) MOLECULAR DYNAMICS INC.
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX PR 04-OCT-2001; 2000US024263.
XX
WPI; 200148897/53.
XX

1 Human genome derived single exon nucleic acid probes useful for
2 and testing gene expression in human placenta -

3 SEQ ID No 33525: 654pp; English.

4 The present invention relates to single exon nucleic acid probes (SENPs:
5 see PCT/US95/157546). The present sequence is a peptide encoded by one
6 such probe. The probes are useful for producing a microarray for
7 prediction, measuring and displaying gene expression in samples derived
8 from human placenta. The probes are useful for antenatal diagnosis of
9 human genetic disorders.

10 Sequence 57 AA:

11 Query Match 70.9% Score 49, PB 22, Length 57;
12 Best Local Similarity 72.7%; Pred. No. 14;
13 Matches 8; Conservative 2; Mismatches 1; Indels 0, Gaps 0;

14 QY 1 ELMRLQDYE 11

15 DB 1B ELMLRLQDYE 28

16 Search completed: January 16, 2003, 16:49:15
17 Job time: 52.3286 secs